Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

(2017) Lene Jensen et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

(2015) Sten Madsbad   DIABETES OBESITY & METABOLISM

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

(2015) Christoph Kapitza et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

(2014) Philippe A. Halban et al.   DIABETES CARE

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

(2012) N. Hex et al.   DIABETIC MEDICINE

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide

(2010) Anne Flint et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY